Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanolimumab + IL-2 in Metastatic Melanoma and Renal Cancer
NCT01160445Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2010
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanolimumab in melanoma, metastatic renal cell carcinoma (mRCC), sponsored by National Cancer Institute. Started Jun 2010; status: terminated.
02
Drugs
zanolimumab
03
Conditions
melanomametastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01160445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160445.